# US 2017/0283803 A1 · Rna interference compositions targeting heat shock protein 90 and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283803 A1
- Document ID: US20170283803A1
- Status: Published application
- Kind: A1
- Application number: 15/326,044
- Filed: 2015-07-14
- Published: 2017-10-05
- Earliest claimed: 2014-07-14
- Assignees: Silenseed Ltd.
- Applicants: Silenseed Ltd.
- Inventors: Amotz SHEMI; Elina ZORDE KHVALEVSKY
- Web page: https://patentgrep.com/patent/US20170283803A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 48/0041: {the non-active part being polymeric}
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/351: Conjugate
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to RNA interference (RNAi) compositions that target expression of heat shock protein 90 (HSP90) in a subject. Polymeric delivery devices for providing the RNAi compositions are also described, as are methods of treating cancer using the described RNAi compositions.

## Claims

### Claim 1

An RNAi (RNA interference) agent for treating a patient having a cancer in which cells of the cancer are expressing heat shock protein 90 (HSP90), the RNAi agent comprising a sense strand and an antisense strand, wherein the RNAi agent targets a sequence selected from the group consisting of SEQ ID Nos 1-3.

### Claim 2

(canceled)

### Claim 3 (depends on 2)

The RNAi agent of claim 2, wherein the sequence of the sense strand comprises a sequence selected from the group consisting of SEQ ID Nos 4-6.

### Claim 4 (depends on 2)

The RNAi agent of claim 2, wherein the sequence of the antisense strand comprises a sequence selected from the group consisting of SEQ ID Nos 8-10.

### Claim 5 (depends on 1)

The RNAi agent of claim 1, wherein at least one of the sense and antisense strands are modified by at least one modification selected from the group consisting of 2′-O-methyl, 2′-O-(2-methoxyethyl), 2′-F, locked nucleic acid (LNA), and phosphorothioate.

### Claim 6 (depends on 5)

The RNAi agent of claim 5, wherein the sense strand comprises SEQ ID NO: 7.

### Claim 7 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent is conjugated to a cholesterol, α-tocopherol moiety, or a cell penetrating peptide.

### Claim 8 (depends on 1)

A drug delivery device (DDD), comprising:
a polymeric matrix; and
at least one RNAi agent of claim 1, wherein the RNAi agent is incorporated within the polymeric matrix.

### Claim 9 (depends on 8)

The DDD of claim 8, further comprising an additive for modulating drug-polymer hydrophobic-hydrophilic interactions.

### Claim 10 (depends on 9)

The DDD of claim 9, wherein the additive is selective from the group consisting of mannitol, trehalose, sorbitol, glucose, fructose, galactose, and sucrose.

### Claim 11

(canceled)

### Claim 12 (depends on 8)

The DDD agent of claim 8, further comprising dTdT at the 3′-end of at least one of the sense and antisense strands.

### Claim 13 (depends on 12)

The DDD agent of claim 12, wherein the sequence of the sense strand comprises a sequence selected from the group consisting of SEQ ID Nos 4-6.

### Claim 14 (depends on 12)

The DDD agent of claim 12, wherein the sequence of the antisense strand comprises a sequence selected from the group consisting of SEQ ID Nos 8-10.

### Claim 15 (depends on 8)

The DDD agent of claim 8, wherein at least one of the sense and antisense strands are modified by at least one modification selected from the group consisting of 2′-O-methyl, 2′-O-(2-methoxyethyl), 2′-F, locked nucleic acid (LNA), and phosphorothioate.

### Claim 16 (depends on 15)

The DDD agent of claim 15, wherein the sense strand comprises SEQ ID NO: 7.

### Claim 17 (depends on 8)

The DDD agent of claim 8, wherein the RNAi agent is conjugated to a cholesterol, α-tocopherol moiety, or a cell penetrating peptide.

### Claim 18 (depends on 8)

The DDD of claim 8, wherein the polymeric matrix comprises a poly(lactic-co-glycolic acid) (PLGA) co-polymer comprising PLA and PGA, and wherein the PLA and the PGA are present in the co-polymer in a ratio of PLA:PGA equal to or larger than 75:25, or equal to or smaller than 25:75.

### Claim 19 (depends on 8)

The DDD of claim 8, further comprising at least one additional RNAi agent that targets a non-HSP90 gene.

### Claim 20

(canceled)

### Claim 21 (depends on 8)

The DDD of claim 8, further comprising polymeric particles, wherein the polymeric particles comprise:
a polymer different from the polymer of the DDD; and
at least one RNAi agent that is incorporated within the DDD matrix.

### Claim 22 (depends on 1)

A method for treating a cancer expressing HSP90 in a subject, comprising:
administering the RNAi agent of claim 1 to the subject, thereby treating the cancer.

### Claim 23 (depends on 8)

A method for treating a solid tumor in a subject, in which cells of the tumor are expressing HSP90, the method comprising:
inserting the DDD of claim 8 into the tumor or tumor bed in the subject, thereby treating the solid tumor.
